OpGen Announces Pricing of Initial Public Offering
May 05 2015 - 8:30AM
OpGen, Inc. (Nasdaq:OPGN) today announced the pricing of its
initial public offering of 2,850,000 units, with each unit
consisting of one share of common stock and a warrant to purchase
one share of common stock, at a combined price to the public of
$6.00 per unit. All of the units are being offered by OpGen.
OpGen's common stock and warrants have been approved for listing on
the NASDAQ Capital Market. The units will immediately and
automatically separate upon issuance, and each of the common stock
and warrants are expected to begin trading separately today, under
the symbols "OPGN" and "OPGNW," respectively. Each warrant will be
immediately exercisable upon issuance for one share of common stock
at an exercise price of $6.60 per share and will expire on May 8,
2020.
OpGen has granted the underwriters the right to purchase up to
an additional 427,500 shares of common stock at a price of $5.99
per share and/or 427,500 additional warrants at a price of $0.01
per warrant less, in each case, the applicable underwriting
discount, within 45 days from the date of this prospectus to cover
over-allotments, if any.
Maxim Group LLC is acting as sole book-running manager and
National Securities Corporation, a wholly owned subsidiary of
National Holdings, Inc. (Nasdaq:NHLD), is acting as co-manager of
the offering.
A registration statement on Form S-1 relating to these
securities was declared effective by the Securities and Exchange
Commission on May 4, 2015. Any offer or sale will be made only by
means of a written prospectus forming part of the effective
registration statement. Copies of the final prospectus relating to
the offering may be obtained from: Maxim Group LLC, 405 Lexington
Ave., 2nd Floor, New York, NY, 10174; by telephone at (800)
724-0761. Copies of the final prospectus relating to the offering
may also be obtained on the Securities and Exchange Commission's
website at http://www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or
jurisdiction.
About OpGen
OpGen, Inc. is an early commercial stage company using molecular
testing and bioinformatics to assist healthcare providers to combat
multi-drug resistant bacterial infections. The company's products
and services are designed to enable the rapid identification of
hospital patients who are colonized or infected with
life-threatening, multi-drug resistant organisms, or MDROs. The
company's lead product is the Acuitas® MDRO Gene Test. Products in
development include the Acuitas Lighthouse™ MDRO Management System
and the Acuitas Resistome Test. In addition, the company has more
than 10 years of experience mapping microbial, plant and human
genomes. Learn more at www.opgen.com.
CONTACT: OpGen
Michael Farmer
Director, Marketing
(240) 813-1284
mfarmer@opgen.com
InvestorRelations@opgen.com
Investors
LHA
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
or
Bruce Voss
(310) 691-7100
bvoss@lhai.com
Media
Lisa Guiterman
(301) 217-9353
lisa.guiterman@gmail.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Oct 2023 to Oct 2024